# Divalproex Sodium (Divalproex Sodium) by AbbVie Inc.: new drug for further processing listing

**Launch Signal Score:** 15/100

| Field | Value |
|---|---|
| Generic name | Divalproex Sodium |
| NDC | 0074-7345 |
| Labeler | AbbVie Inc. |
| Product type | DRUG FOR FURTHER PROCESSING |
| Approval pathway | DRUG FOR FURTHER PROCESSING |
| Dosage form | TABLET, DELAYED RELEASE |
| Active ingredients | DIVALPROEX SODIUM 125 mg/1 |
| Marketing start | 2026-09-22 |
| Package configurations | 1 |

## Why this score


Source: U.S. FDA National Drug Code (NDC) Directory via openFDA (https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=0074-7345). Last refreshed: 2026-11-04T18:12:05.743Z.
Listing data comes from the FDA NDC directory via openFDA; a listing is not an FDA approval or endorsement and may be updated or withdrawn. Informational only; not medical advice.